The role of serum monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs) in cardiovascular disease risk.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
12 05 2021
12 05 2021
Historique:
received:
02
02
2020
accepted:
27
03
2020
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Fatty acids have been observed as independent risk factors of cardiovascular diseases (CVD). In this study we investigated FFA levels in patients with CVD, and, its risk factors. In this case-control study, 346 unrelated Iranian patients who underwent coronary angiography were enrolled. Participants were categorized into two groups: who had >50% stenosis were assigned to the angiogram positive group (N=90) and those with <30% stenosis were assigned to the angiogram negative group (N=124) and also 222 subjects were healthy. Several risk factors were assessed in all participants, including anthropometric indices, blood pressure, lipid profiles, and biochemical factors. The levels of FFAs were determined using gas chromatography. Serum FFA concentrations were compared between healthy and patients with positive and negative angiograms. The association of serum FFA levels with four major risk factors (hypertension, high fasting blood glucose (FBG) level, high BMI and WHR) were also assessed. According to our data, it has been shown that median of FFAs was higher in patients than healthy subjects (p<0.0001), such as SFA and n6-FFAs (in patients 1.59 (1.27) and 1.22 (1.06), respectively and healthy subjects 0.33 (0.38) and 0.36 (0.35)). According to anthropometric and biochemical data, we did not show statistical differences between the groups, except FBG, SBP and hs-CRP that showed significantly higher levels in the patients than controls (p<0.0001, p=0.001). Also, lower median levels of total cholesterol, LDL-C, HDL-C and DBP were observed in patients which can due to lipid-lowering medication use like Statins. High serum levels of FFAs are considered as an independent risk factor for CVDs, while various types of FFAs can have different influences on CVD risk factors. Therefore, longitudinal studies are needed to clarify the association between FFAs and CVD risk factors. High serum levels of FFAs are considered as an independent risk factor for CVDs, while various types of FFAs can have different influences on CVD risk factors. Therefore, longitudinal studies are needed to clarify the association between FFAs and CVD risk factors.
Sections du résumé
BACKGROUND
Fatty acids have been observed as independent risk factors of cardiovascular diseases (CVD). In this study we investigated FFA levels in patients with CVD, and, its risk factors.
MATERIAL AND METHODS
In this case-control study, 346 unrelated Iranian patients who underwent coronary angiography were enrolled. Participants were categorized into two groups: who had >50% stenosis were assigned to the angiogram positive group (N=90) and those with <30% stenosis were assigned to the angiogram negative group (N=124) and also 222 subjects were healthy. Several risk factors were assessed in all participants, including anthropometric indices, blood pressure, lipid profiles, and biochemical factors. The levels of FFAs were determined using gas chromatography. Serum FFA concentrations were compared between healthy and patients with positive and negative angiograms. The association of serum FFA levels with four major risk factors (hypertension, high fasting blood glucose (FBG) level, high BMI and WHR) were also assessed.
RESULTS
According to our data, it has been shown that median of FFAs was higher in patients than healthy subjects (p<0.0001), such as SFA and n6-FFAs (in patients 1.59 (1.27) and 1.22 (1.06), respectively and healthy subjects 0.33 (0.38) and 0.36 (0.35)). According to anthropometric and biochemical data, we did not show statistical differences between the groups, except FBG, SBP and hs-CRP that showed significantly higher levels in the patients than controls (p<0.0001, p=0.001). Also, lower median levels of total cholesterol, LDL-C, HDL-C and DBP were observed in patients which can due to lipid-lowering medication use like Statins.
CONCLUSION
High serum levels of FFAs are considered as an independent risk factor for CVDs, while various types of FFAs can have different influences on CVD risk factors. Therefore, longitudinal studies are needed to clarify the association between FFAs and CVD risk factors. High serum levels of FFAs are considered as an independent risk factor for CVDs, while various types of FFAs can have different influences on CVD risk factors. Therefore, longitudinal studies are needed to clarify the association between FFAs and CVD risk factors.
Identifiants
pubmed: 33988177
doi: 10.23750/abm.v92i2.9235
pmc: PMC8182619
doi:
Substances chimiques
Fatty Acids, Monounsaturated
0
Fatty Acids, Unsaturated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2021049Références
J Mol Endocrinol. 2011 Nov 21;47(3):315-26
pubmed: 21994216
Arteriosclerosis. 1982 Mar-Apr;2(2):87-113
pubmed: 7039582
Diabetes. 2003 Dec;52(12):2882-7
pubmed: 14633847
Trends Cardiovasc Med. 2004 Feb;14(2):72-6
pubmed: 15030793
Am J Epidemiol. 1988 Jan;127(1):75-86
pubmed: 3276162
Herz. 2002 Nov;27(7):621-36
pubmed: 12439634
J Cell Commun Signal. 2014 Dec;8(4):385-91
pubmed: 25387453
J Clin Diagn Res. 2013 Nov;7(11):2432-4
pubmed: 24392364
Curr Opin Lipidol. 2004 Feb;15(1):25-30
pubmed: 15166805
Circulation. 2005 Apr 19;111(15):1883-90
pubmed: 15837940
Int J Cardiol. 2013 Oct 15;168(6):5126-34
pubmed: 23978367
Cytokine. 1999 May;11(5):334-46
pubmed: 10328873
Eur Heart J. 2007 Nov;28(22):2763-9
pubmed: 17766282
Nutrients. 2017 Apr 28;9(5):
pubmed: 28452961
J Clin Invest. 1994 Jun;93(6):2438-46
pubmed: 8200979
Am J Clin Nutr. 1995 May;61(5):1129-39
pubmed: 7733039
J Cell Physiol. 2019 Jul;234(7):10289-10299
pubmed: 30548615
Free Radic Biol Med. 2000 Jun 15;28(12):1815-26
pubmed: 10946223
Int J Environ Res Public Health. 2015 Jun 09;12(6):6582-90
pubmed: 26067991
Heart Rhythm. 2014 Apr;11(4):691-6
pubmed: 24418168
Lancet. 2004 Nov 13-19;364(9447):1786-8
pubmed: 15541452
Diabetes Care. 1979 Mar-Apr;2(2):120-6
pubmed: 520114
Lipids. 2001 Sep;36(9):1007-24
pubmed: 11724453
Am J Epidemiol. 2001 Feb 1;153(3):292-8
pubmed: 11157417
Am J Cardiol. 2012 Jul 15;110(2):212-6
pubmed: 22503582
Circulation. 2002 Apr 30;105(17):2107-11
pubmed: 11980692
Scand J Clin Lab Invest. 1987 Apr;47(2):105-10
pubmed: 3576115
Int J Clin Lab Res. 1998;28(3):192-5
pubmed: 9801932
Ann Intern Med. 1977 Oct;87(4):393-7
pubmed: 199096
Immun Ageing. 2018 Jun 15;15:14
pubmed: 29983721
Am J Clin Nutr. 1994 Dec;60(6 Suppl):986S-990S
pubmed: 7977157
Circulation. 2001 May 22;103(20):2441-6
pubmed: 11369683
Atherosclerosis. 2014 Mar;233(1):104-12
pubmed: 24529130
Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1952-9
pubmed: 16020749
Cardiovasc Diabetol. 2010 Feb 16;9:9
pubmed: 20158910
Atherosclerosis. 2002 Feb;160(2):377-84
pubmed: 11849661
BMC Cardiovasc Disord. 2016 Feb 01;16:29
pubmed: 26830193
JAMA. 2003 Apr 2;289(13):1675-80
pubmed: 12672736
Am J Clin Nutr. 1997 May;65(5 Suppl):1645S-1654S
pubmed: 9129504
Br J Clin Pharmacol. 2016 May;81(5):807-18
pubmed: 26624855
Lipids Health Dis. 2015 Jul 07;14:67
pubmed: 26149129
Am J Clin Nutr. 1965 Nov;17(5):281-95
pubmed: 5846902
CMAJ. 2010 Sep 21;182(13):1427-32
pubmed: 20643837
Am Heart J. 1982 Jun;103(6):1031-9
pubmed: 7044082
J Clin Endocrinol Metab. 2004 Feb;89(2):463-78
pubmed: 14764748
Obes Facts. 2015;8(2):147-55
pubmed: 25895754
J Clin Invest. 1997 Sep 1;100(5):1230-9
pubmed: 9276741
Mol Cell Biochem. 1997 Jan;166(1-2):85-94
pubmed: 9046024
Hypertension. 1996 Feb;27(2):303-7
pubmed: 8567056
Metabolism. 1965 Jul;14(7):776-87
pubmed: 25286466
Prostaglandins Leukot Essent Fatty Acids. 1994 Aug;51(2):101-8
pubmed: 7972262
Br Med J (Clin Res Ed). 1982 Oct 9;285(6347):993-6
pubmed: 6812744
CNS Neurosci Ther. 2013 Apr;19(4):252-61
pubmed: 23521913
Nutr Metab (Lond). 2017 Jun 26;14:41
pubmed: 28674554
Int J Cardiol. 2011 Oct 20;152(2):218-24
pubmed: 20692055
J Clin Invest. 2000 Aug;106(4):453-8
pubmed: 10953019
Circulation. 2003 Jul 29;108(4):426-31
pubmed: 12860913
Am J Clin Nutr. 1986 Sep;44(3):336-40
pubmed: 2875645
J Clin Endocrinol Metab. 2006 Jul;91(7):2542-7
pubmed: 16595593
Res Exp Med (Berl). 1979 Jul 20;175(3):287-91
pubmed: 482737
Arterioscler Thromb. 1992 Aug;12(8):911-9
pubmed: 1386252
J Clin Endocrinol Metab. 2003 Jul;88(7):3005-10
pubmed: 12843134
Ann Transl Med. 2016 Jul;4(13):256
pubmed: 27500157
Heart Vessels. 2013 Jan;28(1):34-8
pubmed: 22187148
Circ Res. 2014 Feb 14;114(4):594-5
pubmed: 24526672
Cardiovasc Diabetol. 2015 Nov 09;14:149
pubmed: 26553117
Clin Chem Lab Med. 2008;46(4):429-34
pubmed: 18605928
Lancet. 1994 Jan 15;343(8890):155-8
pubmed: 7904009
Am J Clin Nutr. 1994 Dec;60(6 Suppl):997S-1001S
pubmed: 7977159